Phase II study of vinorelbine and low-dose docetaxel in chemotherapy-naive patients with hormone-refractory prostate cancer

Cancer Journal

Volumn 9, Issue 4, 2003, Pages 286-292

  Koletsky, Alan J ^a,c   Guerra, Manuel L ^b   Kronish, Lori ^a  

^a Boca Raton Comprehensive Cancer Center   (United States)

^b Oncology and Radiation Associates   (United States)

^c Center for Hematology Oncology   (United States)

Author keywords

Chemotherapy naive; Docetaxel; Hormone refractory prostate cancer; Myelosuppression; Prostate specific antigen; Vinca alkaloid; Vinorelbine

Indexed keywords

ANTIANDROGEN; ANTIBIOTIC AGENT; BILIRUBIN; DOCETAXEL; NAVELBINE; PROSTATE SPECIFIC ANTIGEN; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TESTOSTERONE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; TAXOID; VINBLASTINE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BONE PAIN; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG INFUSION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ERYTHROCYTE TRANSFUSION; FEBRILE NEUTROPENIA; FEVER; HUMAN; IRRITABLE COLON; LOW DRUG DOSE; MALE; MULTICENTER STUDY; NEUROTOXICITY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; TESTOSTERONE BLOOD LEVEL; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT PLANNING; URINARY TRACT INFECTION; BLOOD; DRUG ADMINISTRATION; MIDDLE AGED; PATIENT SELECTION; PROSTATE TUMOR;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; HUMANS; MALE; MIDDLE AGED; PATIENT SELECTION; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TAXOIDS; TESTOSTERONE; TREATMENT OUTCOME; VINBLASTINE;

EID: 0642276507     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/00130404-200307000-00011     Document Type: Article

References (20)

1. Jemal A, Thomas A, Murray T et al. Cancer statistics, 2002. CA Cancer J Clin 2002;52:23-47.
2. Hellerstedt BA, Pienta KJ. The current state of hormonal therapy for prostate cancer. CA Cancer J Clin 2002;52:154-179.
3. Depierre A, Chastang C, Quoix E et al. Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: a randomized trial. Ann Oncol 1994;5:37-42.
4. Fumoleau P, Delgado FM, Delozier T et al. Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 1993;11:1245-1252.
5. Oudard S, Caty A, Humblet Y et al. Phase II study of vinorelbine in patients with androgen-independent prostate cancer. Ann Oncol 2001;12:847-852.
6. Ngan VK, Bellman K, Panda D et al. Novel actions of the antitumor drugs vinflunine and vinorelbine on microtubules. Cancer Res 2000;60:5045-5051.
7. Beer TM, Pierce WC, Lowe BA et al. Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer. Ann Oncol 2001;12:1273-1279.
8. Pienta KJ. Preclinical mechanisms of action of docetaxel and docetaxel combinations in prostate cancer. Semin Oncol 2001;28[suppl 15]:3-7.
9. Kreis W, Calabro A, Budman DR et al. Synergy of Navelbine (vinorelbine) with conventional chemotherapeutic agents in human prostate cancer cell lines in vitro [abstract]. Proc Am Soc Clin Oncol 2001;20:156b.
10. Kornek GV, Ulrich-Pur H, Penz M et al. Treatment of advanced breast cancer with vinorelbine and docetaxel with or without human granulocyte colony-stimulating factor. J Clin Oncol 2001;19:621-627.
11. Brugnatelli S, Riccardi A, Danova M et al. Sequential docetaxel and vinorelbine for patients with advanced breast cancer previously treated with anthracyclines: a phase II study. Oncol Rep 2001;8:801-805.
12. Leu KM, Kim KM, Larson M et al. Phase I/II trial of docetaxel and vinorelbine in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. Lung Cancer 2001;34:105-113.
13. Johnston E, Crawford J, Garst J et al. Phase I trial of weekly docetaxel (D) and vinorelbine (V) in advanced non-small cell lung cancer (NSCLC) [abstract]. Proc Am Soc Clin Oncol 1999;18:476a.
14. Bubley GJ, Carducci M, Dahut W et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations fromthe Prostate-Specific Antigen Working Group. J Clin Oncol 1999;17:3461-3467.
15. Levine EG, Halabi S, Roberts JD et al. Higher doses of mitoxantrone amongmen with hormone-refractory prostate carcinoma: a Cancer and Leukemia Group B study. Cancer 2002;94:665-672.
16. Tannock IF, Osoba D, Stockler MR et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996;14:1756-1764.
17. Hudes GR, Nathan F, Khater C et al. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J Clin Oncol 1997;15:3156-3163.
18. Sitka Copur M, Ledakis P, Lynch J et al. Weekly docetaxel and estramustine in patients with hormone-refractory prostate cancer. Semin Oncol 2001;28[suppl 15]:16-21.
19. Savarese DM, Halabi S, Hars V et al. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B. J Clin Oncol 2001;19:2509-2516.
20. Colleoni M, Gaion F, Vicario G et al. Pain at tumor site after vinorelbine injection: description of an unexpected side effect. Tumori 1995;81:194-196.